Vincerx Pharma urges stockholders to vote for dissolution proposal Jul 7, 2025 04:06PM
Vincerx Pharma (VINC) Announces Intent to Delist from Nasdaq and Deregister with the SEC Apr 17, 2025 04:45PM
Vincerx Pharma (VINC) Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities Apr 8, 2025 04:05PM
Vincerx Pharma (VINC) Announces Non-Binding Letter of Intent for Business Combination with QumulusAI Mar 18, 2025 08:53AM
Vincerx Pharma (VINC) Halted, News Pending Mar 18, 2025 08:40AM


Feb 28, 2025 04:06PM Vincerx Pharma (VINC) Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
Feb 28, 2025 04:00PM Vincerx Pharma (VINC) Halted, News Pending
Jan 29, 2025 08:01AM Vincerx Pharma (VINC) and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
Jan 24, 2025 04:10PM Vincerx Pharma (VINC) Files $100M Mixed Shelf
Jan 23, 2025 04:05PM Vincerx Pharma (VINC) Announces 1:20 Reverse Share Split
Dec 27, 2024 04:06PM Vincerx Pharma (VINC) into a Binding Term Sheet to Merge with Oqory
Dec 4, 2024 06:46AM Vincerx Pharma (VINC) to Implement Cost-Controls
Nov 12, 2024 05:10PM Vincerx Pharma, Inc. (VINC) Tops Q3 EPS by 5c
Oct 8, 2024 09:20AM Vincerx Pharma (VINC) PT Lowered to $2 at Leerink Partners
Oct 7, 2024 04:06PM Vincerx Pharma (VINC) Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study
Aug 8, 2024 04:50PM Vincerx Pharma, Inc. (VINC) Tops Q2 EPS by 16c